OUR TEAM
SarcoMed USA is comprised of experienced biotech entrepreneurs with strong drug development expertise, including Sarcoidosis clinical advisors. The company has initiated a human open label study using Generium’s biosimilar DNase1, in a Proof-of-Concept study in Kazakhstan.
SARCOMED USA LEADERSHIP TEAM
Leveraging our leadership team’s proven expertise in discovering and developing groundbreaking medicines from emerging biological fields, we are applying their combined knowledge to create important new therapies for patients with critical unmet medical needs.
SARCOMED USA ADVISORS
The SarcoMed USA advisors draw on their diverse backgrounds and experiences to provide guidance on our program strategies.
ABOUT SARCOMED USA
SarcoMed USA was formed to investigate if an inhaled DNase 1 therapy could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients.
